Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands

Journal of Clinical Epidemiology

Volumn 88, Issue , 2017, Pages 140-147

  van den Bogert, Cornelis A ^a,b,c   Souverein, Patrick C ^a   Brekelmans, Cecile T M ^b   Janssen, Susan W J ^c   Koëter, Gerard H ^b   Leufkens, Hubert G M ^a   Bouter, Lex M ^d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Central Committee on Research Involving Human Subjects (CCMO)   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical Drug Development; Clinical trial; Discontinuation; Futility; Interim analysis; Recruitment failure

Indexed keywords

ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DATA BASE; DRUG EFFICACY; FOLLOW UP; HUMAN; MULTICENTER STUDY (TOPIC); NETHERLANDS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; EARLY TERMINATION OF CLINICAL TRIAL; PATIENT SELECTION; PROFESSIONAL STANDARD; SAMPLE SIZE; STATISTICS AND NUMERICAL DATA;

DRUG;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; COHORT STUDIES; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; NETHERLANDS; PATIENT SELECTION; PHARMACEUTICAL PREPARATIONS; SAMPLE SIZE;

EID: 85020097451     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2017.05.001     Document Type: Article

References (39)

1. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321 (1989), 406–412.
2. Pocock, S.J., When (not) to stop a clinical trial for benefit. JAMA 294 (2005), 2228–2230.
3. van der Graaf, R., van Delden, J.J., Equipoise should be amended, not abandoned. Clin Trials 8 (2011), 408–416.
4. Bassler, D., Montori, V.M., Briel, M., Glasziou, P., Guyatt, G., Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol 61 (2008), 241–246.
5. Pocock, S., White, I., Trials stopped early: too good to be true?. Lancet 353 (1999), 943–944.
6. Pocock, S.J., Stone, G.W., The primary outcome is positive—is that good enough?. N Engl J Med 375 (2016), 971–979.
7. Montori, V.M., Devereaux, P.J., Adhikari, N.K., Burns, K.E., Eggert, C.H., Briel, M., et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294 (2005), 2203–2209.
8. ICH Harmonised Tripartite guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 18 (1999), 1905–1942.
9. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Eur Comm Offic J Eur Union 158 (2014), 1–76.
10. Kasenda, B., von Elm, E., You, J., Blumle, A., Tomonaga, Y., Saccilotto, R., et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 311 (2014), 1045–1051.
11. Schroen, A.T., Petroni, G.R., Wang, H., Gray, R., Wang, X.F., Cronin, W., et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 7 (2010), 312–321.
12. van den Bogert, C.A., Souverein, P.C., Brekelmans, C.T., Janssen, S.W., van Hunnik, M., Koeter, G.H., et al. Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study. BMJ Open, 5(7), 2015, e007827.
13. van den Bogert, C.A., Souverein, P.C., Brekelmans, C.T., Janssen, S.W., Koeter, G.H., Leufkens, H.G., et al. Non-publication is common among phase 1, single-center, not prospectively registered, or early terminated clinical drug trials. PLoS One, 11, 2016, e0167709.
14. Tasks of the CCMO (webpage). Available at http://www.ccmo.nl/en/tasks-of-the-ccmo. Accessed August 31, 2016.
15. List of accredited IRBs in the Netherlands (webpage). Available at http://www.ccmo.nl/en/accredited-mrecs. Accessed August 5, 2016.
16. Decullier, E., Lheritier, V., Chapuis, F., Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ, 331, 2005, 19.
17. Easterbrook, P.J., Matthews, D.R., Fate of research studies. J R Soc Med 85:2 (1992), 71–76.
18. Pich, J., Carne, X., Arnaiz, J.A., Gomez, B., Trilla, A., Rodes, J., Role of a research ethics committee in follow-up and publication of results. Lancet 361 (2003), 1015–1016.
19. Stern, J.M., Simes, R.J., Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 315 (1997), 640–645.
20. von Elm, E., Rollin, A., Blumle, A., Huwiler, K., Witschi, M., Egger, M., Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly 138:13–14 (2008), 197–203.
21. Carlisle, B., Kimmelman, J., Ramsay, T., MacKinnon, N., Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clin Trials 12 (2015), 77–83.
22. Briel, M., Olu, K.K., von Elm, E., Kasenda, B., Alturki, R., Agarwal, A., et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol 80 (2016), 8–15.
23. Thabane, L., Ma, J., Chu, R., Cheng, J., Ismaila, A., Rios, L.P., et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol, 10, 2010, 1.
24. Head, M.L., Holman, L., Lanfear, R., Kahn, A.T., Jennions, M.D., The extent and consequences of p-hacking in science. PLoS Biol, 13(3), 2015, e1002106.
25. Stegert, M., Kasenda, B., von Elm, E., You, J.J., Blumle, A., Tomonaga, Y., et al. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. J Clin Epidemiol 69 (2016), 152–160.
26. Trotta, F., Apolone, G., Garattini, S., Tafuri, G., Stopping a trial early in oncology: for patients or for industry?. Ann Oncol 19 (2008), 1347–1353.
27. Nawaz, K., Webster, R.M., The non-small-cell lung cancer drug market. Nat Rev Drug Discov 15:4 (2016), 229–230.
28. Casazza, G., Casella, F., Can we trust in trials stopped early for benefit?. Intern Emerg Med 7:6 (2012), 559–561.
29. Heffner, A.C., Milbrandt, E.B., Venkataraman, R., Trials stopped early for benefit? Not so fast!. Crit Care, 11(1), 2007, 305.
30. Blumle, A., Schandelmaier, S., Oeller, P., Kasenda, B., Briel, M., von Elm, E., et al. Premature discontinuation of prospective clinical studies approved by a research ethics committee—a comparison of randomised and non-randomised studies. PLoS One, 11, 2016, e0165605.
31. Damen, L., van Agt, F., de Boo, T., Huysmans, F., Terminating clinical trials without sufficient subjects. J Med Ethics 38 (2012), 413–416.
32. Vermeer, N.S., Duijnhoven, R.G., Straus, S.M., Mantel-Teeuwisse, A.K., Arlett, P.R., Egberts, A.C., et al. Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in Europe. Clin Pharmacol Ther 96 (2014), 723–731.
33. Alturki, R., Schandelmaier, S., Olu, K.K., von Niederhausern, B., Agarwal, A., Frei, R., et al. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. J Clin Epidemiol 81 (2017), 56–63.
34. Moore, N., Lessons from the fatal French study BIA-10-2474. BMJ, 353, 2016, i2727.
35. Lievre, M., Menard, J., Bruckert, E., Cogneau, J., Delahaye, F., Giral, P., et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ 322 (2001), 603–605.
36. Evans, S., Pocock, S., Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial. BMJ 322 (2001), 569–570.
37. Pocock, S.J., Size of cancer clinical trials and stopping rules. Br J Cancer 38 (1978), 757–766.
38. Pocock, S.J., When to stop a clinical trial. BMJ 305 (1992), 235–240.
39. Grant, A.M., Altman, D.G., Babiker, A.B., Campbell, M.K., Clemens, F.J., Darbyshire, J.H., et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess 9 (2005), 1–238 iii-iv.